Search Result

Results for "

cAMP+levels

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Adenylate Cyclase (3) Adhesion G Protein-coupled Receptors (AGPCRs) (1) Adrenergic Receptor (2) Akt (4) Amyloid-β (1) Antibiotic (1) AP-1 (1) Apoptosis (1) Calcium Channel (3) Cannabinoid Receptor (1) CCR (1) Cholinesterase (ChE) (1) Collagen (1) CXCR (2) Drug Derivative (2) Endogenous Metabolite (3) ERK (3) Estrogen Receptor/ERR (1) Ferroptosis (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (2) Gli (1) GLP Receptor (1) Glutathione Reductase (GR) (1) GPR119 (1) GSK-3 (1) Interleukin Related (2) JNK (1) Microtubule/Tubulin (1) MOFs (1) mTOR (1) NF-κB (2) P2Y Receptor (2) p38 MAPK (5) Parasite (2) Phosphodiesterase (PDE) (23) Phospholipase (1) PI3K (1) PKA (3) Potassium Channel (1) PPAR (2) Prostaglandin Receptor (3) Reference Standards (3) Ser/Thr Protease (1) Succinate Receptor 1 (1) Tau Protein (1) Thymidylate Synthase (1) TNF Receptor (2) Transmembrane Glycoprotein (2) TRP Channel (1) Tyrosinase (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (16) Endocrinology (8) Infection (2) Inflammation/Immunology (18) Metabolic Disease (11) Neurological Disease (9)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (1)

Adenylate Cyclase (3)

Adhesion G Protein-coupled Receptors (AGPCRs) (1)

Adrenergic Receptor (2)

Akt (4)

Amyloid-β (1)

Antibiotic (1)

AP-1 (1)

Apoptosis (1)

Calcium Channel (3)

Cannabinoid Receptor (1)

CCR (1)

Cholinesterase (ChE) (1)

Collagen (1)

CXCR (2)

Drug Derivative (2)

Endogenous Metabolite (3)

ERK (3)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

GABA Receptor (2)

Gli (1)

GLP Receptor (1)

Glutathione Reductase (GR) (1)

GPR119 (1)

GSK-3 (1)

Interleukin Related (2)

JNK (1)

Microtubule/Tubulin (1)

MOFs (1)

mTOR (1)

NF-κB (2)

P2Y Receptor (2)

p38 MAPK (5)

Parasite (2)

Phosphodiesterase (PDE) (23)

Phospholipase (1)

PI3K (1)

PKA (3)

Potassium Channel (1)

PPAR (2)

Prostaglandin Receptor (3)

Reference Standards (3)

Ser/Thr Protease (1)

Succinate Receptor 1 (1)

Tau Protein (1)

Thymidylate Synthase (1)

TNF Receptor (2)

Transmembrane Glycoprotein (2)

TRP Channel (1)

Tyrosinase (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (16)

Endocrinology (8)

Infection (2)

Inflammation/Immunology (18)

Metabolic Disease (11)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2118

Bilobetin 2 Publications Verification	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-P4860

Adropin (34-76) (human, mouse, rat) 1 Publications Verification	Akt Gli JNK PKA	Metabolic Disease
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit *cAMP* level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .

HY-125791

cis-Epoxysuccinic acid 3 Publications Verification	Succinate Receptor 1	Cardiovascular Disease
cis-Epoxysuccinic acid is a succinate receptor (SUCNR1/GPR91) agonist. cis-Epoxysuccinic acid inhibits cAMP levels with an EC₅₀ value of 2.7 μM. cis-Epoxysuccinic acid can be used for the research of cardiovascular system .

HY-15478

WZ811 3 Publications Verification	MOFs CXCR	Endocrinology Cancer
WZ811 is an orally active, highly potent competitive antagonist of CXCR4. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC₅₀=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC₅₀=5.2 nM) .

HY-19929

Tanimilast CHF-6001	Phosphodiesterase (PDE) NF-κB Interleukin Related CXCR CCR TNF Receptor	Inflammation/Immunology
Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC₅₀=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases .

HY-B0327

Irsogladine 3 Publications Verification Dicloguamine	Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related	Inflammation/Immunology Cancer
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and K_ATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer ^[5][6] .

HY-128879A

VP3.15 dihydrobromide	Phosphodiesterase (PDE) GSK-3 Tau Protein	Cardiovascular Disease Neurological Disease Inflammation/Immunology
VP3.15 dihydrobromide is a highly potent, orally bioavailable, and CNS-penetrant PDE7-GSK3 dual inhibitor, with IC₅₀ values of 1.59 μM and 0.88 μM against PDE7 and GSK3, respectively . VP3.15 dihydrobromide elevates intracellular *cAMP* levels, suppresses immune responses, enhances remyelination, limits excessive tau phosphorylation, and alleviates neuroinflammation and neuronal loss. VP3.15 dihydrobromide promotes oligodendrocyte precursor cell differentiation, improves in vivo remyelination, inhibits autoimmune encephalomyelitis, and mitigates germinal matrix-intraventricular hemorrhage-related brain injury, cerebral atrophy, ventricular enlargement, and cognitive impairment. VP3.15 dihydrobromide can be used in research related to multiple sclerosis and germinal matrix-intraventricular hemorrhage .

HY-108618

BC11-38 2 Publications Verification	Phosphodiesterase (PDE)	Endocrinology
BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC₅₀s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces *cAMP* levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-136637

NPD-001	Phosphodiesterase (PDE) Parasite	Infection
NPD-001 is a potent Trypanosoma brucei phosphodiesterases 1/2 (TbrPDEB1/2) inhibitor, with IC₅₀ values of 4 and 3 nM, respectively. NPD-001 also inhibits hPDE4. NPD-001 can increase cAMP levels in parasites, prevent cytokinesis, and cause the parasites to form multinucleated, multi-flagellated cells that eventually lyse. NPD-001 can be used for the research of infection .

HY-P5189A

His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA	Endogenous Metabolite Cholinesterase (ChE)	Others
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .

HY-P3570

Adipokinetic hormone II (Locusta migratoria) Lom-AKH-II	Endogenous Metabolite	Metabolic Disease
Adipokinetic hormone II (Locusta migratoria) (Lom-AKH-II) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .

HY-100936

Etazolate hydrochloride SQ 20009; EHT 0202 hydrochloride	Phosphodiesterase (PDE) GABA Receptor	Neurological Disease Inflammation/Immunology
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC₅₀ of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABA_A) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .

HY-170788

PDE7A-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE7A-IN-1 is an orally active and selective PDE7A inhibitor with an IC₅₀ of 0.0037 μM against PDE7A. PDE7A-IN-1 shows excellent isozyme selectivity over PDE7B. PDE7A-IN-1 elevates intracellular *cAMP* levels, suppresses ECR5 enhancer activity and reduces sclerostin expression. PDE7A-IN-1 significantly increases bone mineral density in rats. PDE7A-IN-1 can be used for the study of osteoporosis .

HY-P3572

Adipokinetic hormone I (Locusta migratoria) Lom-AKH-I	Endogenous Metabolite	Endocrinology
Adipokinetic hormone I (Locusta migratoria) (Lom-AKH-I) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .

HY-P10365

VPM-p15	Adhesion G Protein-coupled Receptors (AGPCRs)	Others
Vmm-p15 is a peptide agonist optimized for the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). The affinity of VPM-p15 with GPR64 is significantly higher than that of the original p15 peptide. The cAMP level induced by VMM-P15 increased significantly, activated GPR64, and triggered downstream Gs, Gq, and G12/13 signaling. VPM-p15 can be used to study the activation mechanism of adherent GPCR family members .

HY-114727

PDE7-IN-4	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases .

HY-178780

MKP10241	GPR119	Metabolic Disease
MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC₅₀: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH .

HY-162394

Vasopressin V2 receptor antagonist 2	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-130629

VHC-7	Adenylate Cyclase	Neurological Disease
VHC-7 is a potent and selective adenylyl cyclase type 8 (AC8) agonist, with an EC₅₀ value of 105.2 nM. VHC-7 increases cyclic adenosine monophosphate (cAMP) levels. VHC-7 can be used for the study of central nervous system disorders and heart diseases .

HY-108623

Atizoram CP-80,633	Phosphodiesterase (PDE)	Inflammation/Immunology
Atizoram (CP-80,633) is an orally active phosphodiesterase type 4 (PDE4) inhibitor. Atizoram blocks cAMP degradation, thereby increasing intracellular and plasma *cAMP* levels. Atizoram inhibits TNFα release. Atizoram can be used in research related to acute respiratory distress syndrome .

HY-137370

2-Hexynyl-5′-N-ethylcarboxamidoadenosine HENECA; 2-Hexynyl-NECA	Adenosine Receptor Amyloid-β	Neurological Disease
2-Hexynyl-5′-N-ethylcarboxamidoadenosine (HENECA) is a selective A_2A adenosine receptor agonist. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine increases intracellular cAMP level, and inhibits TNFα-evoked MMP-3 release. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine induces Aβ42 production in SH-SY5Y cells .

HY-179407

LT-104A	Phosphodiesterase (PDE)	Inflammation/Immunology
LT-104A is a potent PDE4 inhibitor that elevates intracellular cAMP levels (EC₅₀ = 1.9 μM) and inhibits PDE4D3 activity (IC₅₀ = 9.3 μM). LT-104A activates the cAMP-PKA-CREB anti-inflammatory signaling pathway and suppresses NF-κB-related gene expression (Il1b and Nos2). LT-104A can be used for inflammation-related disease research .

HY-171850

GLP-1R modulator-1	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-116540A

L 858051 dihydrochloride 7DMB-Forskolin	Adenylate Cyclase	Cardiovascular Disease
L 858051 (7DMB-Forskolin) dihydrochloride, an analog of Forskolin (HY-15371), is an adenylyl cyclase stimulator. L 858051 dihydrochloride directly activates adenylyl cyclase to increase intracellular, cellular, and ciliary cAMP levels. L 858051 dihydrochloride activates recombinant cyclic nucleotide-gated (E583M CNGA2) channels to induce a non-selective, Mg ²⁺-sensitive current in adult rat ventricular myocytes. L 858051 dihydrochloride maximally stimulates L-type Ca ²⁺ current in adult rat ventricular myocytes. L 858051 dihydrochloride increases total PDE3 and PDE4 activities in adult rat ventricular myocytes, with effects insensitive to PKA inhibition. L 858051 dihydrochloride serves as a tool to elevate intracellular cAMP for studying subsarcolemmal cAMP dynamics and compartmentation in adult rat ventricular myocytes .

HY-179504

PDE4B-IN-6	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4B-IN-6 (compound 4i) is a potent and selective PDE4B inhibitor with an IC₅₀ of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over PDE4A (IC₅₀ = 1540 nM) and PDE4C (IC₅₀ = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research .

HY-105912

ONO 1082	Drug Derivative	Endocrinology
ONO 1082 is a Prostaglandin E1 (PGE1) (HY-B0131) derivative and increases cAMP level in hepatocytes. ONO 1082 competes with the action of the cholestatic factor through the increase in the cAMP level .

HY-114948

Rimiterol	Adrenergic Receptor	Endocrinology
Rimiterol is a selective β2-adrenergic receptor agonist. Rimiterol activates adenylate cyclase and elevates intracellular cAMP levels to cause smooth muscle relaxation. Rimiterol is promising for research of asthma .

HY-105482

BMY 20844	Phosphodiesterase (PDE)	Cardiovascular Disease
BMY 20844 is an orally active platelet cAMP phosphodiesterase inhibitor with anti-thrombosis activity. BMY 20844 can elevate cAMP levels and activate protein kinase in platelets. BMY 20844 can be used for the research of cardiovascular disease .

HY-137308

15(R)-Prostaglandin D2 15R-PGD2	Prostaglandin Receptor	Inflammation/Immunology
15(R)-Prostaglandin D2 is a potential prostatic hormone DP(2) receptor (Prostaglandin Receptor) agonist with anti-inflammatory activity. 15(R)-Prostaglandin D2 increases actin polymerization in human eosinophils and increases cAMP levels in platelets .

HY-106893

Pimilprost SM 10902	Drug Derivative Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Pimilprost (SM 10902) is a prostaglandin I1 analogue. Pimilprost exhibits antithrombotic and increases cAMP levels. Pimilprost can promote wound healing through the stimulation of angiogenesis and the improvement of blood flow in diabetic mice. Pimilprost can be used for the research of metabolic and cardiovascular disease, such as diabetes .

HY-131664

EP3 antagonist 2	Prostaglandin Receptor	Others
EP3 antagonist 2 (Compound Exp 1) is a potent and selective EP3 receptor antagonist. EP3 antagonist 2 has a strong binding affinity for the human EP3 receptor (K_i: 3.3 nM) and significant antagonistic activity (IC₅₀: 30.8 nM, determined by cellular cAMP levels) .

HY-129210

KMUP-4	Phosphodiesterase (PDE) Potassium Channel	Cardiovascular Disease
KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterases (PDEs) and activating K ⁺ channels. KMUP-4 can be used in the study of cardiovascular diseases .

HY-170908

Pellotine	5-HT Receptor	Neurological Disease
Pellotine is an alkaloid that can be isolated from Lophophora. Pellotine is the inverse agonist for 5-HT7 receptor with an EC₅₀ of 291 nM. Pellotine exhibits good affinity to 5-HT1DR and 5-HT6R with K_i of 117 nM and 170 nM. Pellotine reduces intracellular cAMP levels, thereby reducing neuronal excitability and neurotransmitter release .

HY-159917

PPL agonist-1	Tyrosinase Microtubule/Tubulin	Inflammation/Immunology
PPL agonist-1 is a highly selective Periplakin (PPL) agonist that increases cAMP levels by regulating PPL, thereby enhancing MITF expression and promoting melanin synthesis. Furthermore, PPL agonist-1 facilitates melanin production by regulating tryptophan metabolism. Compared to Ruxolitinib (HY-50856), PPL agonist-1 demonstrates superior efficacy. PPL agonist-1 holds potential for research into vitiligo treatment .

HY-124371

Amentoflavone hexaacetate	Phosphodiesterase (PDE)	Cardiovascular Disease
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .

HY-126250

NPD-1335	Phosphodiesterase (PDE) Parasite	Infection Inflammation/Immunology
NPD1335 is a Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) inhibitor with submicromolar activities against T. brucei parasites. NPD1335 displays a greatly improved cytotoxicity profile. NPD1335 increases intracellular cAMP levels and results in the distortion of the cell cycle and cell death . NPD-1335 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0113A

Hordenine sulfate Ordenina sulfate; Peyocactine sulfate	Antibiotic	Others
Hordenine sulfate (Ordenina sulfate) is an active compound extracted from malted barley that has melanin-inhibiting activity. Hordenine sulfate significantly reduced melanin content and reduced intracellular cAMP levels. Hordenine sulfate inhibits the expression of proteins related to melanogenesis, including microblind transcription factor (MITF), tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2. Therefore, Hordenine sulfate can be used as an active ingredient to inhibit pigmentation .

HY-100936R

Etazolate hydrochloride (Standard) SQ 20009 (Standard); EHT 0202 hydrochloride (Standard)	Reference Standards Phosphodiesterase (PDE) GABA Receptor	Neurological Disease Inflammation/Immunology
Etazolate (hydrochloride) (Standard) is the analytical standard of Etazolate (hydrochloride). This product is intended for research and analytical applications. Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .

HY-N2118R

Bilobetin (Standard)	Reference Standards PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-120246

GS-5759	Adrenergic Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
GS-5759 is both a β₂-adrenergic receptor agonist and a PDE4 inhibitor. GS-5759 increases intracellular cAMP levels by activating the β₂ receptor, promoting bronchial dilation. GS-5759 inhibits PDE4 activity, reduces cAMP degradation, and enhances anti-inflammatory effects. GS-5759 exhibits potent bronchial dilation and anti-inflammatory capabilities in animal models. GS-5759 can be used for research on respiratory diseases such as chronic obstructive pulmonary disease (COPD) .

HY-176520

PDE4-IN-29	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-29 (Compound 55) is an orally active and selective PDE4 inhibitor (including subtypes such as PDE4A1, PDE4B2, PDE4D3) with IC₅₀s of <5 nM against PDE4D3. PDE4-IN-29 inhibits the degradation of cyclic adenosine monophosphate (cAMP), increases intracellular cAMP levels, suppressing the release of inflammatory factors such as TNF-α. PDE4-IN-29 is promising for research of inflammatory diseases including psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease .

HY-116295

MRS2690	P2Y Receptor p38 MAPK Calcium Channel	Cardiovascular Disease
MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [ ³⁵S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease .

HY-116295A

MRS2690 disodium	P2Y Receptor p38 MAPK Calcium Channel	Cardiovascular Disease
MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [ ³⁵S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease .

HY-116540

L 858051 7DMB-Forskolin free base	Adenylate Cyclase	Cardiovascular Disease
L 858051 (7DMB-Forskolin free base), an analog of Forskolin (HY-15371), is an adenylyl cyclase stimulator. L 858051 directly activates adenylyl cyclase to increase intracellular, cellular, and ciliary cAMP levels. L 858051 activates recombinant cyclic nucleotide-gated (E583M CNGA2) channels to induce a non-selective, Mg ²⁺-sensitive current in adult rat ventricular myocytes. L 858051 maximally stimulates L-type Ca ²⁺ current in adult rat ventricular myocytes. L 858051 increases total PDE3 and PDE4 activities in adult rat ventricular myocytes, with effects insensitive to PKA inhibition. L 858051 serves as a tool to elevate intracellular cAMP for studying subsarcolemmal cAMP dynamics and compartmentation in adult rat ventricular myocytes .

HY-182452

U 84569	Phosphodiesterase (PDE) Phospholipase	Cardiovascular Disease
U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC₅₀ value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating *cAMP* levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation .

HY-167201

2ccPA	Collagen	Others
2ccPA is a Cyclic phosphatidic acid derivative. 2ccPA decreases ECM expression, increases the intracellular *cAMP* levels. 2ccPA decreases the protein expression levels of type I collagen, CCN2 and αSMA. 2ccPA has inhibitory effects on the progression of skin fibrosis by abrogating ECM production from activated skin fibroblasts .

HY-181738

GPR17 agonist 2	Transmembrane Glycoprotein	Cardiovascular Disease Neurological Disease
GPR17 agonist 2 (compound 10) is a human GPR17 agonist and selective P2Y receptor non-activator.GPR17 agonist 2 modulates intracellular cAMP levels through functional activation of its target receptor.GPR17 agonist 2 can be used for the research of multiple sclerosis, cerebral ischemia, traumatic brain injury, spinal cord injury .

HY-183657A

GPR3 inverse agonist-1 TFA		Neurological Disease
GPR3 inverse agonist-1 TFA is a selective and competitive GPR3 inverse agonist with an EC₅₀ of 5 μM. GPR3 inverse agonist-1 TFA inhibits GPR3-dependent Gs activity, stabilizes a specific receptor conformation, and reduces cAMP levels. GPR3 inverse agonist-1 TFA can be used for the research of Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area